143 related articles for article (PubMed ID: 37095029)
1. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
Islam J; Shree A; Vafa A; Afzal SM; Sultana S
Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
[No Abstract] [Full Text] [Related]
2. Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway.
Islam J; Shree A; Vafa A; Afzal SM; Sultana S
Int Immunopharmacol; 2021 Jul; 96():107566. PubMed ID: 33813368
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Epigallocatechin gallate potentially abrogates fluoride induced lung oxidative stress, inflammation via Nrf2/Keap1 signaling pathway in rats: An in-vivo and in-silico study" [Int. Immunopharmacol. 39 (2016) 128-139].
Shanmugam T; Selvaraj M; Poomalai S
Int Immunopharmacol; 2020 Mar; 80():106203. PubMed ID: 31983588
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187].
Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791
[No Abstract] [Full Text] [Related]
5. Corrigendum to "Salidroside postconditioning attenuates ferroptosis-mediated lung ischemia-reperfusion injury by activating the Nrf2/SLC7A11 signaling axis" [Int. Immunopharmacol. 115 (2023) 109731].
Wang Y; Chen Z; Luo J; Zhang J; Sang AM; Cheng ZS; Li XY
Int Immunopharmacol; 2023 Apr; 117():110002. PubMed ID: 36925352
[No Abstract] [Full Text] [Related]
6. Corrigendum to "7-Deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signalling" [Int. Immunopharmacol. 107 (2022) 108557].
Chen J; Zhu G; Sun Y; Wu Y; Wu B; Zheng W; Ma X; Zheng Y
Int Immunopharmacol; 2023 Sep; 122():110640. PubMed ID: 37524574
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int. Immunopharmacol. 77 (2019) 105968].
Jiang Y; Hu F; Li Q; Shen C; Yang J; Li M
Int Immunopharmacol; 2020 Jul; 84():106318. PubMed ID: 32115350
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Ghrelin attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3 inflammasome activation and promoting Nrf2/ARE signaling pathway in mice" [Int. Immunopharmacol. 79 (2020) 106180].
Cheng Y; Chen B; Xie W; Chen Z; Yang G; Cai Y; Shang H; Zhao W
Int Immunopharmacol; 2020 Jul; 84():106461. PubMed ID: 32278662
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Methyl helicterilate ameliorates alcohol-induced hepatic fibrosis by modulating TGF-β1/Smads pathway and mitochondria-dependent pathway" [Int. Immunopharmacol. 75 (2019) 105759].
Wen S; Wei Y; Zhang X; Bai F; Tan S; Nie J; Wei J; Lin X
Int Immunopharmacol; 2021 Mar; 92():107344. PubMed ID: 33418247
[No Abstract] [Full Text] [Related]
10. Corrigendum to "Rotundic acid ameliorates non-alcoholic steatohepatitis via SREBP-1c/SCD1 signaling pathway and modulating gut microbiota" [Int. Immunopharmacol. 99 (2021) 108065].
Liu HJ; Cao ST; Wen BY; Han X; Li Y; Li S; Li J; Zhang L
Int Immunopharmacol; 2023 Dec; 125(Pt A):111084. PubMed ID: 37879973
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice" [Int. Immunopharmacol. 59 (2018) 269-275].
Luo S; Deng X; Liu Q; Pan Z; Zhao Z; Zhou L; Luo X
Int Immunopharmacol; 2018 Sep; 62():337. PubMed ID: 29983242
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Baccatin III ameliorates bleomycin-induced pulmonary fibrosis via suppressing TGF-β1 production and TGF-β1-induced fibroblasts differentiation" [Int Immunopharmacol. 74 (2019) 105696].
Nie Y; Zhang D; Qian F; Wu Y
Int Immunopharmacol; 2022 Mar; 104():108496. PubMed ID: 35016851
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 128 (2024) https://doi.org/10.1016/j.intimp.2023.111466].
Geng H; Zhang H; Cheng L; Dong S
Int Immunopharmacol; 2024 Apr; 131():111873. PubMed ID: 38514302
[No Abstract] [Full Text] [Related]
14. Corrigendum to "4-Hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice" [Int. Immunopharmacol. 83 (2020) 106445].
Wang H; Wei X; Wei X; Sun X; Huang X; Liang Y; Xu W; Zhu X; Lin X; Lin J
Int Immunopharmacol; 2020 Sep; 86():106722. PubMed ID: 32593975
[No Abstract] [Full Text] [Related]
15. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
Zhang Y; Ji T; Ma S; Wu W
Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Gypsophila elegans isoorientin-2″-O-α-L-arabinopyranosyl ameliorates porcine serum-induced immune liver fibrosis by inhibiting NF-κB signaling pathway and suppressing HSC activation" [Int. Immunopharmacol. 54 (2018) 60-67].
Bai F; Huang Q; Wei J; Lv S; Chen Y; Liang C; Wei L; Lu Z; Lin X
Int Immunopharmacol; 2023 Sep; 122():110697. PubMed ID: 37500383
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Zerumbone enhances the Th1 response and ameliorates ovalbumin-induced Th2 responses and airway inflammation in mice" [Int. Immunopharmacol. 24 (2015) 383-391].
Shieh YH; Huang HM; Ching-Chiung Wang ; Lee CC; Fan CK; Lee YL
Int Immunopharmacol; 2017 Sep; 50():371. PubMed ID: 28751107
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway" [Int. Immunopharmacol. 36 (2016) 132-141].
Yao H; Hu C; Yin L; Tao X; Xu L; Qi Y; Han X; Xu Y; Zhao Y; Wang C; Peng J
Int Immunopharmacol; 2019 Sep; 74():105786. PubMed ID: 31402320
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Icariin targets Nrf2 signaling to inhibit microglia-mediated neuroinflammation" [Int. Immunopharmacol. 73 (2019) 304-311].
Zheng Y; Zhu G; He J; Wang G; Li D; Zhang F
Int Immunopharmacol; 2020 Nov; 88():107004. PubMed ID: 32950402
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function" [Int. Immunopharmacol. (2015) 423-432].
Sun J; Shen X; Dong J; Zhao J; Zuo L; Wang H; Li Y; Zhu W; Gong J; Li J
Int Immunopharmacol; 2016 Jun; 35():341. PubMed ID: 27130814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
